Gamma Biosciences, a global life sciences company in the advanced therapy market, has agreed to make a controlling investment in Mirus Bio, a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, WI.
 
The transaction will support Mirus’ plans to expand GMP production and commercialization of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further development and commercialization of the platform for in vivo delivery applications. Originally developed for therapeutic delivery of RNA, Mirus LPNCs have been adapted for a wide range of gene delivery applications. Demand for efficient and scalable gene delivery technologies continues to increase as larger volumes of viral vector are required to support the growing number of gene therapies in development.
 
TransIT VirusGen and Mirus’ portfolio of additional products and services enable customers at both research and clinical scales achieve cost effective functional titers.
 
Mirus will leverage Gamma Bio’s strategic and commercial resources and will work closely with its other companies, including Univercells Technologies, Astrea Bioseparations, Nanopareil and BioMagnetic Solutions, to deliver a comprehensive range of services for the advanced therapy industry.